Featured Article
Precision Oncology Today
Magazine
Minimal Disease, Maximum Benefit
As both flow cytometry technology and genomic sequencing have taken technological leaps forward, the sensitivity and specificity of testing has increased to include MRD for solid tumors. Leveraging advances in next-generation sequencing, MRD test developers can look for thousands of disease markers and even detect one cancerous cell among a million healthy cells. This level of sensitivity provides evidence of disease recurrence months before traditional follow-up screening methods.
Immunogenomics is on the Way Up
Combining immune-system science, omics, and various computational algorithms might produce success where advanced cancer treatments have failed.
Trending on Inside Precision Medicine
Study Sheds Light on How Aging Immune System Drives Cancer Development
The research details how the aging immune system contributes to tumor growth and offers potential new avenues for cancer prevention, particularly for older adults.
Gastrointestinal Chemotherapy Tweak Can Reduce Side Effects
Simply using 5-fluorouracil infusion and omitting the initial bolus, quick-delivery injection in multi-drug chemotherapy regimens for advanced gastrointestinal cancers can reduce treatment toxicity without affecting survival, a study suggests.
eGenesis Raises $191 Million for Gene Edited Pig Organs
Xenotransplantation pioneer eGenesis has closed a $191 million financing that will go toward advancing the company's lead candidate, EGEN-2784, a first-in-human study for kidney transplant.